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Abstract Ubiquinone 0 and decylubiquinone have been reported
to inhibit the mitochondrial permeability transition pore (PTP)
[Fontaine, E., Ichas, F. and Bernardi, P. (1998) J. Biol. Chem.
273, 25734^25740], offering a new clue to its molecular com-
position. In patch-clamp experiments on rat liver mitochondria
we have observed that these compounds also inhibit the
previously described mitochondrial megachannel (MMC), con-
firming its identification as the PTP. Inhibition can be reversed
by increasing [Ca2+], in analogy to the behavior observed with
several other disparate PTP/MMC inhibitors. To rationalize the
ability of Ca2+ to overcome inhibition by various quite different
compounds we propose that it acts via the phospholipid
bilayer. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The mitochondrial permeability transition (PT; [1^3]), pro-
posed to be a key early event in several models of apoptosis
[4^10], is due to the opening of the ‘permeability transition
pore’ (PTP) in the mitochondrial membrane system. Despite
much work, what proteins form the PTP remains to be estab-
lished. The adenine nucleotide translocator (AdNT) has long
been the leading candidate (e.g. [2,11]). Today most authors in
the ¢eld however favor the idea that PTP is a supramolecular
complex comprising proteins of the matrix (cyclophilin D), of
the inner (e.g. the AdNT) and outer (voltage-dependent anion
channel (porin) (VDAC), perhaps Bax) mitochondrial mem-
branes and of the periplasmic space (creatine kinase) (e.g.
[2,4,5,12,13]). The pore has long been considered to reside in
the inner mitochondrial membrane, since its activation leads
to e¥ux of soluble matrix components such as NADH and to
swelling due to the in£ux of osmotically active species. How-
ever, since supramolecular assemblies of AdNT, kinases and
VDAC are known to be present at sites of contact between
the two membranes [14], and, upon isolation and reconstitu-
tion, exhibit PTP-like properties [4,15,16], the notion has tak-
en hold that the PTP might be located at these sites. The
proposal has also been made that it might be a manifestation
of the mitochondrial protein import complex [17,18]. The dis-
coveries that the PTP is modulated by electron £ow through
Complex I, and that it can be inhibited by ubiquinone ana-
logues [19,20], have led to the hypothesis that the PTP might
arise from, or include, this part of the respiratory chain. In-
deed, the possibility exists that di¡erent variants of the PTP
might form, depending on experimental conditions.
A high-conductance (1^1.3 nS in 100 mM KCl), substate-
rich pore observed by patch-clamping swollen mitoplasts (the
mitochondrial megachannel, MMC) [21,22] has been identi-
¢ed as the PTP on the basis of its properties and of its phar-
macological pro¢le [23^25].
The properties and the complex pharmacology of the PTP
have been extensively investigated. The PT is induced by a
variety of conditions and agents, and inhibited by a similarly
imposing array of compounds [1,2]. Two key features are the
requirement for matrix Ca2 for PTP activation and its volt-
age-dependence: opening is facilitated by depolarization
[26,27]. The e¡ects of many inducers and inhibitors have
been interpreted as shifts of the threshold potential for pore
opening [28,29]. A striking feature, still waiting for a satisfac-
tory explanation, is that inhibition by disparate key agents
(protons, cyclosporin, divalent cations, local anesthetics) can
be counteracted by increases of [Ca2]matrix, in an apparently
competitive fashion. Ca2 also antagonizes vi, in the sense
that at higher Ca2 loads lower extents of depolarization are
needed to induce the PT. This behavior has been clearly ob-
served in patch-clamp experiments, in which sequential addi-
tions of ever-increasing concentrations of Ca2 and divalent
cations (Sr2, Mn2, Ba2, Mg2), protons or CSA result in
the correlated activation/inhibition of the PTP [24,25]. Where-
as the idea that Ca2 and other divalent cations may compete
for the same binding sites on (a) protein(s) is reasonable, it
seems unlikely that the same binding sites are involved in the
case of other agents mentioned above. An explanation for
their competitive behavior must therefore be sought.
Here we report that the ubiquinone analogues and PTP
inhibitors ubiquinone 0 (Ub0) and decylubiquinone (decylUb)
also inhibit the MMC in patch-clamp experiments, thus con-
¢rming the identity PTPrMMC. Also in the case of these
compounds, and of ADP, inhibition can be counteracted by
increasing [Ca2]. We propose that Ca2-induced modi¢ca-
tions of the properties of the lipid bilayer may underlie this
antagonistic behavior.
2. Materials and methods
Patch-clamp experiments on rat liver mitoplasts were conducted
essentially as previously described [21,23^25]. The standard experi-
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mental medium (the same in both bath and pipette) was 150 mM KCl,
0.1^1.0 mM CaCl2, 20 mM HEPES/K, pH 7.2. In most experiments
1 or 2 s long voltage pulses, separated by 0.1 s intervals at zero
potential, were sequentially applied to the pipette electrode. The po-
larity of the voltage was inverted after each pulse, and low potentials
(most often þ 10 or þ 20 mV) were used. This type of protocol en-
sures that the megachannels will not inactivate because of their volt-
age dependence; there was no evidence of ‘channel rundown’. In ex-
periments involving inhibition by ubiquinone analogues, stationary
megachannel activity was recorded for a few minutes and 50^200 Wl
of medium containing 10^20 Wg/ml BSA to help solubilization and the
desired amount of inhibitor (from a stock solution in DMSO) were
then added to the bath by pipetting. To re-activate the pores, CaCl2
was added as a few Wl of stock solution. In most (11/13) reversal-of-
inhibition experiments with Ub5 (see Section 3), mitoplasts were in-
cubated with Ub0 for about 15 min to inhibit the MMCs, a tight seal
was then established in the presence of the inhibitor, and Ub5 was
added after verifying that megachannel activity was absent. The po-
tentials reported in this paper are those applied to the pipette. Current
(cations) £owing from the pipette to the ground electrode are consid-
ered positive and plotted upwards. Ub0, Ub5, decylUb and ADP were
from Sigma (Milan, Italy).
3. Results
Typical MMC activity was observed in nearly all attempts
after establishment of tight seals on mitoplasts. In the experi-
ments reported here most patches exhibited activity by more
than one MMC (up to 10). We tested the inhibitory e¡ect of
Ub0 on the MMC by adding the compound at a ¢nal con-
centration of 50 or 200 WM to the solution bathing a pipette-
attached whole mitoplast (Fig. 1). This experimental con¢gu-
ration presumably accounts for the fact that inhibition was
slow, requiring a few minutes to reach its maximum extent,
since the inhibitor had to di¡use to the patch held by the
pipette. The active MMCs were inhibited in an apparently
sequential manner, disappearing ‘one after the other’ over a
period of minutes. Total or partial inhibition of the active
MMC channels in the patch by 50 WM Ub0 took place in
12 out of 17 experiments, in which the seals lasted 2^19 min
after the addition and mixing. In ¢ve experiments there was
no clear inhibitory e¡ect. However, in these ¢ve cases the seals
lasted 1^3.5 min after addition, and this shorter lifetime prob-
ably accounts at least partially for the lack of inhibition. In
30 other experiments Ub0 was added at a ¢nal concentration
of approximately 200 WM. Extensive inhibition took place in
22 cases. In the remaining eight the seals lasted less than 2 min
after addition of the inhibitor, again presumably accounting
for the lack of e¡ect.
Re-activation of MMC activity by increasing the concen-
tration of Ca2 in the bath was attempted in four cases in
which inhibition had been achieved by 50 WM Ub0 and in six
of the experiments in which the channels had been inhibited
by 200 WM Ub0, [Ca2]bath was shifted from 0.5^1 to 4^
11 mM. In all cases channel activity was re-established after
a delay. Reactivation apparently occurred in a stepwise man-
ner, analogous to the inhibition process.
DecylUb behaved analogously (Fig. 2). In 14 experiments
the compound was added at a ¢nal concentration of 200^450
WM. In 11 cases the channels were extensively or completely
inhibited within 1^10 min. In the three other experiments,
conducted with 200 or 330 WM decylUb, the tight seal held
for less than 3 min after the addition. Increasing [Ca2]bath to
5 mM resulted in the re-establishment of channel activity in
all seven attempts made.
In experiments with suspensions of rat liver mitochondria
(RLM), Ub5 did not prevent the onset of the PT in Ca2-
loaded mitochondria, and it relieved instead the inhibition
caused by Ub0 or decylUb [20]. In patch-clamp experiments
this compound was similarly unable to inhibit the MMC at
concentrations up to 100 WM (not shown; n = 5). To verify
whether it would revert the e¡ects of Ub0, after inhibiting
MMC activity with 50^240 WM Ub0 we applied 120^
450 WM Ub5 to pipette-attached mitoplasts. In 11 out of
13 experiments the addition was followed, after a variable
delay, by the development of transmembrane currents. How-
ever this activity only sporadically resembled MMC gating.
Instead, it generally exhibited fast, £ickering gating which
might or might not be due to MMCs operating in a kinetic
mode originated by a competition between Ub0 and Ub5 (Fig.
3).
Once inhibited by Ub0 or decylUb, the channels seldom re-
Fig. 1. Ca2-reversible inhibition of MMC activity by Ub0. A repre-
sentative experiment is illustrated. A: A mean current plot: consecu-
tive 1 s þ 10 mV voltage pulses, separated by 100 ms periods at
0 mV, were applied to a mitoplast-attached patch. The current £ow-
ing during each pulse was averaged and plotted as a function of
time. The medium contained 1 mM Ca2. Additions to the chamber
(where indicated): Ub0 : 250 nmol (¢nal concentration: 216 WM);
CaCl2 : 5.4 Wmol (¢nal concentration: 5.5 mM). The segment indi-
cated is plotted below as part B. B: A segment of the current rec-
ord comprising the Ub0-induced closure of the last active MMC.
Sampling: 1 kHz. Filter: 0.5 kHz. The section denoted by ‘C’ is
plotted on an ampli¢ed time scale in part C. C: The closure of the
last MMC to be inhibited by Ub0. Sampling: 5 kHz. Filter: 1 kHz.
Capacitive current spikes, corresponding to voltage changes to/from
0 from/to þ 10 mV, have been reduced for clarity in these and all
other current traces presented.
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opened completely unless [Ca2]bath was increased. When they
did, they remained active for seconds, and displayed the nor-
mal pattern of transitions to substates (favored by pipette-
negative potentials). Thus, the presence of these inhibitors
appears not to result in marked alterations of the behavior
of the open channels. Most full closing or re-opening events
took place via brief sojourns in substates, generally in the fast-
gating ‘half-conductance’ substate already described [21,25].
MMCs closing or opening ‘spontaneously’ or under the in£u-
ence of voltage often display the same behavior. Patches in
which MMC activity had been practically eliminated by these
inhibitors also exhibited, besides gating by 107 pS channels
[30], rare bursts attributable to MMCs operating in a fast-
gating subconductance state. Fig. 4 presents an exemplary
gallery of events recorded from inhibited patches.
Our attempts at re-inhibiting the Ca-reactivated channels
by increasing the concentration of Ub0 or decylUb invariably
failed due to loss of the tight seal. It is therefore unclear
whether repetitive inhibition/reactivation cycles can be carried
out with these ubiquinone analogues in analogy to the behav-
ior with other inhibitors, exempli¢ed in Fig. 5 in the case of
ADP.
4. Discussion
The results presented above demonstrate that the MMCs
observed in patch-clamp experiments are inhibited by Ub0
and decylUb, and not by Ub5, in analogy with the inhibition
of the PTP in isolated, suspended mitochondria [19,20]. This
Fig. 3. E¡ect of Ub5. A: A mean current plot analogous to those
in Figs. 1A and 2A. Conditions as in Fig. 1A. Additions to the
chamber, when indicated: Ub0 : 50 WM; Ub5 : 200 WM (¢nal concen-
trations). A record segment at the position denoted by ‘B’ is plotted
below. B: A segment of the current record after Ub5 addition. Digi-
tal sampling: 1 kHz. Filtering: 0.5 kHz.
Fig. 4. Current traces illustrating bursts of MMC activity in Ub0-in-
hibited patches. Sampling: 5 kHz. Filtering: 1 kHz.
Fig. 2. Ca2-reversible inhibition of MMC activity by decylUb. A:
A mean current plot analogous to the one in Fig. 1A. Conditions
as in Fig. 1A. [Ca2]medium : 0.5 mM. Additions: decylUb: 0.5 Wmol
(¢nal concentration: 450 WM). Ca2 : 5.4 Wmol (¢nal concentration:
5.3 mM). The current trace of the segment denoted by ‘B’ is plotted
below. B: The initial stages of channel reactivation after Ca2 addi-
tion. Sampling: 1 kHz. Filter: 500 Hz. C: A segment of the record
in B showing the Ca2-induced opening of the ¢rst MMC, plotted
on an ampli¢ed time scale. Digital sampling: 5 kHz. Filtering:
1 kHz.
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con¢rms the identi¢cation of the MMC as the electrophysio-
logical counterpart of the PTP. Furthermore, our observa-
tions con¢rm the conclusion that inhibition by these com-
pounds is due to direct interactions rather than to an
inhibitory e¡ect on electron £ow, since in patch-clamped mi-
toplasts (osmotically shocked, permeabilized by PTP opening
and incubated in a respiratory substrate-free medium) little
electron transport ought to take place. The channels inhibited
by Ub0 and decylUb are the same that are closed by an array
of other PTP inhibitors. They are therefore, presumably,
formed by the same proteins, whose identity remains uncer-
tain. The action of ubiquinone analogues and PTP modula-
tion by electron £ow through Complex I suggest that the
latter may be involved [19,20]. On the other hand, other
data strongly implicate the AdNT as well as other proteins,
including VDAC. It may be that the PTP is even more com-
plex than imagined so far, including, but probably not limited
to, components of the respiratory chain as well as the AdNT.
Ligand-induced changes in the conformation of one or the
other of these components may result in its closure/inactiva-
tion/disassembly.
One interesting aspect is the fact that inhibition by Ub0,
decylUb and ADP could be reverted by increasing the
[Ca2] in the medium. These compounds thus join the list of
the MMC/PTP inhibitors which can be competitively antago-
nized by Ca2. The present results and previous work with
other inhibitors ([25] ; Szabo' and Zoratti, unpublished obser-
vations) suggests that the activating Ca2 binding sites are not
saturated in the mM concentration range. Since the closest
thing to an unsaturable Ca2 binding site in mitochondria
are the membrane phospholipids, it seems reasonable to sug-
gest that at least part of the Ca2 e¡ects, at high Ca2 con-
centrations, may be exerted at the membrane level.
Ca2 is known to form ion pairs with the negatively
charged groups of acidic lipids, which are abundant in mito-
chondrial membranes [31]. These interactions modify the sur-
face charge and potential of the membrane, leading to a cor-
responding variation of the electrical ¢eld sensed by
membrane-embedded charged groups in proteins. Since the
e¡ects of several PTP inhibitors have been ascribed to varia-
tions of the sensitivity of the pore complex to depolarization
(a shift of the threshold potential for opening to more depo-
larized values) [28,29], this might be considered to explain why
Ca2 binding to the inner surface of the inner membrane can
reverse their e¡ect. Indeed, for example, the action of AdNT
ligands (atractyloside, bongkrekate, ADP) has been proposed
to be mediated by variations of surface potential secondary to
AdNT conformational changes [32^34]. However, in our elec-
trophysiological experiments very low potentials ( þ 10 or 20
mV) were routinely applied, i.e. the mitochondrial membrane
was always essentially depolarized. Furthermore, while Ca2
could re-activate inhibited channels, this e¡ect was not pro-
duced by the application of matrix-positive potentials, which
should in principle be equivalent to make the potential of the
matrix-side inner membrane surface more positive by Ca2
binding.
The Ca2 e¡ect is thus likely to have other explanations.
Ca2 binding to negatively charged phospholipids (PS, PA,
cardiolipin) induces ‘rigidi¢cation’ and phase separation (e.g.
[35^40]) which may well in£uence protein activity. Changes in
membrane order and/or £uidity might favor the aggregation
of the inner membrane proteins needed to form the PTP com-
Fig. 5. Competition between Ca2 and ADP. A: A mean current plot. In this experiment V was held at +40 mV. The current (leaks sub-
tracted) was averaged over 5 s consecutive intervals, and the means are plotted sequentially. The medium contained 0.1 mM Ca2 and the bath
volume was approximately 1 ml. When indicated by the arrows, Ca2 (t) or ADP (s) was added to the bath. The amount added was
100 nmol unless otherwise speci¢ed by the numbers above the arrows. The patch initially displayed only 107 pS channels. Addition of a total
of 300 nmol of Ca2 elicited, after a lag, activity by two MMCs, which was promptly inhibited upon addition of 100 nmol of ADP. One of
the channels was reactivated by the addition of more Ca2, again inhibited by ADP, reactivated by Ca2, reinhibited by ADP and reactivated
once more by Ca2 before loss of the tight seal. Where indicated by an asterisk gaps appear in the record because of excessive noise introduced
by the additions. The current trace corresponding to the segment marked ‘B’ is shown below. B: The opening of one MMC upon readdition
of Ca2 after the ¢rst inhibition by ADP in the same experiment illustrated above. The current record corresponding to the segment marked
by a ‘B’ in Fig. 5A is shown. The channel opens and closes via sojourns in the ‘half-conductance state’, as it typically does. Sampling: 1 kHz.
Filter: 0.5 kHz.
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plex, or the conformational changes needed to open the pore.
PTP inhibitors are generally considered to act by hindering
pore assembly or the relevant changes in protein structure
rather than as blockers. PTP components may therefore be
considered to exist as unproductive species, stabilized by
bound inhibitors or by the lack of some other partner in
the complex, or as PTP-producing forms, favored, in this
hypothesis, by Ca2-induced membrane modi¢cations. The
system would therefore be described as an equilibrium, whose
position would obviously be regulated by thermodynamic fac-
tors. Increasing the concentration of inhibitors would drive it
towards ‘closed-pore’ state(s) simply by mass action. Increas-
ing [Ca2] would drive it towards ‘open-pore’ states by mak-
ing the membrane environment more and more favorable for
PTP activity. Some inhibitors and activators (e.g. trivalent
cations, polyamines, local anesthetics, peptides like mastopar-
an [41]) probably act directly through alterations of the mem-
brane state.
Another hypothesis might envision Ca2-induced hemifu-
sion of the outer and inner mitochondrial membranes. High
[Ca2] has long been known to be aggregating and fusogenic
(e.g. [42]), ¢nding application for example in the fusion of
mitoplasts [43]. Fusion of model phospholipid bilayers [44]
as well as protein-mediated fusion (e.g. [45^47]) are believed
to proceed via the formation of hemifusion intermediates
which then progress to fusion pores. The fusion process can
be stopped at the hemifusion stage using mutagenized fusion
proteins [48,49]. Mitochondria can undergo fusion with other
mitochondria in vivo (e.g. [50,51]) and with liposomes in vitro
(e.g. [52,53]) as well as lipid exchange between organelles
[54,55]. Their outer membrane has been recently demonstrated
to contain fusogenic proteins [56^58] and they might harbor a
v-SNARE [59]. Mitochondria form contact sites between the
inner and outer membranes for both protein import (e.g. [60])
and energy conservation [14] purposes. Morphological evi-
dence has been presented that Ca2-induced organizational
changes of the mitochondrial membranes promote the forma-
tion of contact sites, proposed to be sites of hemifusion be-
tween the two membranes ([14] and references therein; [39]).
At these locations the mitochondrion would be bound by a
single bilayer, or by a non-bilayer lipidic structure, in which
proteins of both inner and outer membranes might mingle,
forming the MMC/PTP. It might even be imagined that the
PTP is actually a mitochondrial version of fusion pore which
does not proceed to enlarge in¢nitely. Fusion pores have been
observed to behave like gating channels (e.g. [45]) and their
formation appears to be reversible (e.g. [61]). It is however
more di⁄cult to explain the antagonistic e¡ect of increases in
the concentration of inhibitors within this mechanistic scheme
unless the assumption is made that, e.g. ADP or cyclosporin
can induce the reversal of the hemifusion process. While this
may sound far-fetched, it should be mentioned that contact
site formation is reportedly regulated by multiple factors, in-
cluding whether the mitochondria are engaged or not in phos-
phorylation [14,62], an e¡ect believed to be mediated by the
AdNT [63] (to which cyclophilin D binds [64]).
In summary, our observations strengthen the hypothesis
that the ¢rst segment of the mitochondrial respiratory chain
may contribute to form the PTP. Furthermore, they suggest
that the phospholipid bilayer itself may be involved in Ca2-
induced MMC/PTP activation. These conclusions are relevant
for studies on cellular processes involving PTP activation,
especially since apoptosis in some models has been associated
with a direct and early interference with mitochondrial respi-
ratory chain function (e.g. [65^67]).
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